Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis

[1]  Norbert Ritter,et al.  State of the Art and Future Directions , 2019, Real-Time & Stream Data Management.

[2]  A. Craig,et al.  Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers , 2017, Breast Cancer Research.

[3]  M. Stack,et al.  Post-translational modification of the membrane type 1 matrix metalloproteinase (MT1-MMP) cytoplasmic tail impacts ovarian cancer multicellular aggregate dynamics , 2017, The Journal of Biological Chemistry.

[4]  S. Loibl,et al.  HER2-positive breast cancer , 2017, The Lancet.

[5]  S. Zahler,et al.  Modulation of actin dynamics as potential macrophage subtype-targeting anti-tumour strategy , 2017, Scientific Reports.

[6]  C. Fichter,et al.  Targeted delivery of an ADP-ribosylating bacterial toxin into cancer cells , 2017, Scientific Reports.

[7]  R. Shah,et al.  HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone. , 2017, Cancer research.

[8]  Feng Jiang,et al.  Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer , 2016, International journal of molecular sciences.

[9]  K. Strasser-Weippl,et al.  Current and emerging therapies of HER2-positive metastatic breast cancer. , 2016, Breast.

[10]  Jacques Haiech,et al.  Cancer Stem Cell Quiescence and Plasticity as Major Challenges in Cancer Therapy , 2016, Stem cells international.

[11]  Yibin Kang,et al.  Distinctive properties of metastasis-initiating cells , 2016, Genes & development.

[12]  A. Vincent-Salomon,et al.  ARF6–JIP3/4 regulate endosomal tubules for MT1-MMP exocytosis in cancer invasion , 2015, The Journal of cell biology.

[13]  T. Schroer,et al.  Mycalolide B dissociates dynactin and abolishes retrograde axonal transport of dense-core vesicles , 2015, Molecular biology of the cell.

[14]  M. Kita,et al.  Marine natural products that interfere with multiple cytoskeletal protein interactions. , 2015, Natural product reports.

[15]  I. Nabi,et al.  Actin Cytoskeleton Regulation of Epithelial Mesenchymal Transition in Metastatic Cancer Cells , 2015, PloS one.

[16]  Christopher M. Fife,et al.  Movers and shakers: cell cytoskeleton in cancer metastasis , 2014, British journal of pharmacology.

[17]  S. Zahler,et al.  The Actin Targeting Compound Chondramide Inhibits Breast Cancer Metastasis via Reduction of Cellular Contractility , 2014, PloS one.

[18]  Sohita Dhillon.  Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy , 2014, Drugs.

[19]  J. Isola,et al.  Trastuzumab emtansine: mechanisms of action and drug resistance , 2014, Breast Cancer Research.

[20]  K. Suenaga,et al.  Apoptosis-inducing activity of the actin-depolymerizing agent aplyronine A and its side-chain derivatives. , 2013, Bioorganic & medicinal chemistry letters.

[21]  Yuichiro Hirayama,et al.  Design, synthesis, and biological evaluations of aplyronine A-mycalolide B hybrid compound. , 2012, Organic letters.

[22]  R. Schiff,et al.  HER 2: Biology, Detection, and Clinical Implications , 2011 .

[23]  Carolina Gutierrez,et al.  HER2: biology, detection, and clinical implications. , 2011, Archives of pathology & laboratory medicine.

[24]  J. Kubanek,et al.  Two molecules of lobophorolide cooperate to stabilize an actin dimer using both their "ring" and "tail" region. , 2010, Chemistry & biology.

[25]  Zhonglei Chen,et al.  Rationally simplified bistramide analog reversibly targets actin polymerization and inhibits cancer progression in vitro and in vivo. , 2010, Journal of the American Chemical Society.

[26]  Anna Adamiak,et al.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy , 2009, BMC Cancer.

[27]  C. Sakakura,et al.  Latrunculin a has a strong anticancer effect in a peritoneal dissemination model of human gastric cancer in mice. , 2009, Anticancer research.

[28]  M. Stack,et al.  Epidermal Growth Factor Receptor–Mediated Membrane Type 1 Matrix Metalloproteinase Endocytosis Regulates the Transition between Invasive versus Expansive Growth of Ovarian Carcinoma Cells in Three-Dimensional Collagen , 2009, Molecular Cancer Research.

[29]  T. Molinski,et al.  Drug development from marine natural products , 2009, Nature Reviews Drug Discovery.

[30]  C. Klein,et al.  The Metastasis Cascade , 2008, Science.

[31]  G. Egea,et al.  Dynamics of an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide , 2008, Journal of Cell Science.

[32]  Ian Paterson,et al.  Synthetic mimetics of actin-binding macrolides: rational design of actin-targeted drugs. , 2008, Chemistry & biology.

[33]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[34]  M. Ringuette,et al.  MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells , 2007, British Journal of Cancer.

[35]  I. Rayment,et al.  Actin-targeting natural products: structures, properties and mechanisms of action , 2006, Cellular and Molecular Life Sciences CMLS.

[36]  A. Puisieux,et al.  Metastasis: a question of life or death , 2006, Nature Reviews Cancer.

[37]  J. Rao,et al.  Microfilament actin remodeling as a potential target for cancer drug development. , 2004, Current cancer drug targets.

[38]  Gabriel Fenteany,et al.  Small-molecule inhibitors of actin dynamics and cell motility. , 2003, Current topics in medicinal chemistry.

[39]  E. Friederich,et al.  The actin cytoskeleton as a therapeutic target: state of the art and future directions. , 2003, Progress in cell cycle research.

[40]  P. Beuzeboc,et al.  Targeting HER2 in other tumor types. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  K. L. Woodward,et al.  A question of life or death. , 2001, Newsweek.

[42]  F. Braet,et al.  New anti‐actin drugs in the study of the organization and function of the actin cytoskeleton , 1999, Microscopy research and technique.

[43]  S. Watabe,et al.  Actin-binding specificity of marine macrolide toxins, mycalolide B and kabiramide D. , 1998, Journal of biochemistry.

[44]  S. Watabe,et al.  Actin-depolymerizing effect of dimeric macrolides, bistheonellide A and swinholide A. , 1998, Journal of biochemistry.

[45]  N. Sato,et al.  The role of the cytoskeleton in migration and proliferation of a cultured human gastric cancer cell line using a new metastasis model. , 1997, Cancer letters.

[46]  Takuma Sasaki,et al.  Halishigamides A-D, new cytotoxic oxazole-containing metabolites from Okinawan sponge Halichondria sp. , 1997 .

[47]  S. Watabe,et al.  Mycalolide B, a novel actin depolymerizing agent. , 1994, The Journal of biological chemistry.

[48]  S. Matsunaga,et al.  Mycalolides A – C, hybrid macrolides of ulapualides and halichondramide, from a sponge of the genus Mycale , 1989 .

[49]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.